Skip to main content
OpenTrials
Completed

NCT Number: NCT05965635

The Uninfected Ixodes Scapularis Human Tick Challenge Model

An innovative way to prevent multiple tick-borne diseases is an anti-tick vaccine, i.e. targeting the vector to prevent transmission of pathogens from the tick to the host. The rationale for an anti-tick vaccine stems from a phenomenon coined tick immunity. This study aims to show proof of concept that humans indeed develop immunity to ticks. Therefore subjects will be challenged three to four times with ticks reared in colony from a designated laboratory and that are exhaustively tested negative for various known tick-borne pathogens. Several tick feeding parameters will be evaluated to assess the development of tick immunity in the subjects. To this end, a total amount of ten ticks per challenge will be placed under a dressing placed on the forearm. The primary study endpoint is the tick feeding phenotype. Secondary parameters are signs of an immune response in the host; itch, redness, or other signs of a (local) immune response (blood and skin biopsies). All parameters, except for the skin biopsies, will be collected/evaluated after each tick challenge.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

AUMC location AMC

Amsterdam-Zuidoost, North Holland, 1105 AZ, Netherlands

About this study

This will be an, single centre, experimental study. The design of the study is similar to a human challenge trial, with the important exception that the subjects in this study are not experimentally infected with a pathogen, but are exposed to well-characterized laboratory-reared uninfected nymphal Ixodes scapularis ticks.

Seven healthy human volunteers of >18 years old who have no history of known tick-bites or tick-borne diseases will be recruited. Subjects will undergo three to four tick challenges, consisting of five to six days per challenge with two weeks between the consecutive challenges. The total duration of participation is approximately five months for each subject. By making use of ticks from a laboratory-reared tick colony that have been, and are being, used in xenodiagnosis and tick challenge models in the USA and that are well tolerated minimizing the risks of the tick challenges. Regardless, the tick challenge can cause some discomfort because of possible local reactions and because the dressing must be kept dry for five to six days. The risk of infection with a tick-borne pathogen is negligible due to the fact that these ticks are exhaustively tested for various known tick-borne pathogens. Finally, risks are considerated of development of a red meat allergy or other allergic reactions negligible because no clear associations are known of I. scapularis ticks and red meat allergy. No serious adverse events (such as human infections or red meat allergy) have resulted from more than >100 challenges in the United States using this tick colony. There are no direct benefits of participation.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age: 18 years and older;
  • Negative Borrelia VlsE1/pepC10 ELISA.

Exclusion criteria

  • Known history of tick bites;
  • Positive Borrelia serology (VlsE1/PepC10 ELISA);
  • Known history or current suspicion on any tick-borne disease;
  • Chronic skin condition affecting the arm skin;
  • Inability to maintain the dressing for any reason;
  • Known immunodeficiency or autoimmune disease;
  • Use of systemic immunomodulating drugs or chemotherapy, current or in the past;
  • Chronic use of antibiotics;
  • Unable to give informed consent or do not have a thorough command of the Dutch language;
  • Refusal to participate in specimen collection and storage for future study related use;
  • Pregnant or breastfeeding women;
  • Not willing to use adequate contraception during the study period;
  • Red meat allergy (both medically confirmed and self-reported);
  • Use of investigational therapy and devices during the time of the study;
  • Any other condition that, in the opinion of the investigator, would make the patient unsuitable for enrolment or could interfere with the patient participating in and completing the study.

Treatment and study plan

Ixodus scapularis nymphs

Other

Tick challenge

Primary outcomes

  1. Tick weight

    Time frame: Up to 1 week

    Tick weight in mg

  2. Tick feeding molting success

    Time frame: Up to 1 week

    Molting success rate

  3. Tick survival

    Time frame: Up to 1 week

    tick survival rate

  4. Tick attachment

    Time frame: Up to 1 week

    tick attachment rate

Secondary outcomes

  1. Signs of an immune response in the host: Itch

    Time frame: Up to 1 week

    Itch

  2. Signs of an immune response in the host: redness

    Time frame: Up to 1 week

    Redness

  3. Signs of an immune response in the host: other

    Time frame: 3 weeks

    Other signs of a local immune response (in blood)

  4. Signs of an immune response in the host: biopsies

    Time frame: 9 weeks

    Other signs of a local immune response (in skin biopsies)

Sponsors and collaborators

Lead sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Other

Collaborators

  • ZonMw: The Netherlands Organisation for Health Research and Development

Registry information

Acronym: TICKME

Important dates

Study start
2023
Primary completion
2026
Study completion
2026
First posted
Jul 28, 2023
Registry last updated
Mar 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.